EirGen Pharma Product Eir-126 Passes Bioequivalence Study in US

EirGen Pharma are pleased to announce that Eir-126, a product which was developed as a steroidal based orally disintegrating tablet has today successfully passed its Bioequivalence Study against the US Reference Product. The market for this product is one with very limited generic competition. We expect to complete our filing to US FDA shortly.